Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Amneal Pharmaceuticals Inc
(NY:
AMRX
)
5.870
UNCHANGED
Last Price
Updated: 7:00 PM EST, Dec 26, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amneal Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
Next >
Amneal Receives 505(b)(2) NDA Approval from FDA for PEMRYDI RTU®, a Ready-to-Use Oncology Injectable
June 14, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal to Participate at the 2023 Jefferies Healthcare Conference
May 24, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Launches Third Biosimilar with FYLNETRA™ (pegfilgrastim-pbbk) in the United States
May 16, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Pharma Q1 Exceeds Consensus View On Strength In Complex Generics Portfolio
May 05, 2023
Via
Benzinga
Recap: Amneal Pharmaceuticals Q1 Earnings
May 05, 2023
Via
Benzinga
Earnings Preview: Amneal Pharmaceuticals
May 04, 2023
Via
Benzinga
Expert Ratings for Amneal Pharmaceuticals
March 29, 2023
Via
Benzinga
Amneal Reports First Quarter 2023 Financial Results
May 05, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Earnings Scheduled For May 5, 2023
May 05, 2023
Companies Reporting Before The Bell • CNH Industrial (NYSE:CNHI) is estimated to report quarterly earnings at $0.32 per share on revenue of $5.08 billion.
Via
Benzinga
Amneal to Participate at the 22nd Annual Needham Virtual Healthcare Conference
April 17, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Reports Certain Preliminary First Quarter 2023 Financial Results and Affirms Full Year 2023 Financial Guidance
April 17, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal to Report First Quarter 2023 Results on May 5, 2023
April 12, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Emergent BioSolutions Soars: Analyst Upgrades Stock With Near 100% Upside After FDA's Positive Move
April 10, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
March 14, 2023
Tuesday's morning session saw 84 companies set new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
March 06, 2023
On Monday, 36 companies set new 52-week lows.
Via
Benzinga
Amneal Announces U.S. FDA Filing Acceptance of Abbreviated New Drug Application for Naloxone Hydrochloride Nasal Spray, USP, 4mg
March 02, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Reports Fourth Quarter and Full Year 2022 Financial Results
March 02, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
March 01, 2023
Via
Benzinga
Amneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023
January 31, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Intercept Surges To Four-Month High After Staving Off Amneal's Generic For 11 Years
January 25, 2023
Intercept entered a deal with Amneal, likely lining up a series of new settlements.
Via
Investor's Business Daily
Amneal Announces Strategic European Partnership with Orion Corporation
January 04, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval
December 20, 2022
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal to Participate at Upcoming Investor Conferences
November 23, 2022
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United States
November 22, 2022
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson’s Disease
November 11, 2022
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Pharmaceuticals: Q3 Earnings Insights
November 04, 2022
Amneal Pharmaceuticals (NYSE:AMRX) reported its Q3 earnings results on Friday, November 4, 2022 at 06:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Amneal Reports Third Quarter 2022 Financial Results
November 04, 2022
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Earnings Outlook For Amneal Pharmaceuticals
November 03, 2022
Amneal Pharmaceuticals (NYSE:AMRX) is set to give its latest quarterly earnings report on Friday, 2022-11-04. Here's what investors need to know before the announcement. Analysts estimate that Amneal...
Via
Benzinga
Amneal Receives FDA Approval for Leuprolide Acetate Injection
November 02, 2022
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Earnings Scheduled For November 4, 2022
November 04, 2022
Companies Reporting Before The Bell • Sprott (NYSE:SII) is likely to report quarterly earnings at $0.49 per share on revenue of $49.95 million. • Telefonica (NYSE:TEF) is likely to report earnings for...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.